Syntara (ASX:SNT)
ASX announcement history & article coverage
Transparent by design.
Announcments by Syntara (ASX:SNT) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notice of Annual General Meeting/Proxy Form
Investor Presentation Canaccord Drug & Device Conference
Further significant results from SNT-4728 iRBD Phase 2 trial
Syntara reports sustained motor improvement with SNT-4728 in Phase 2 Parkinson's risk study
Notification regarding unquoted securities - SNT
Notification regarding unquoted securities - SNT
Syntara expands SNT-9465 skin scarring study
Syntara expands SNT-9465 scar study to 30 participants, with results due Q1 2027
Syntara receives A$4.7m R&D Tax Incentive
Application for quotation of securities - SNT
Notification of 2026 AGM Date
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report
Syntara reports higher loss on lower revenue; advances clinical pipeline with FDA support and $8.8M capital raise
Investor Update Webinar Presentation
Investor Update Webinar
Investor Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
Syntara advances clinical trials with FDA support and $8M capital raise, extends cash runway to Q3 2027
